Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: cabazitaxel

Summary for Generic Name: cabazitaxel

Drug Master File Entries: see list8
Suppliers: see list1

Clinical Trials for: cabazitaxel

Cabazitaxel - PF Induction Chemotherapy
Status: Recruiting Condition: Squamous Cell Carcinoma of the Head and Neck

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Status: Recruiting Condition: Urothelium Transitional Cell Carcinoma

Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Status: Recruiting Condition: Non-small Cell Lung Cancer (NSCLC); Stage IV NSCLC; Metastatic NSCLC

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Status: Terminated Condition: Neoplasms, Malignant

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Status: Withdrawn Condition: Castrate-resistant Metastatic Prostate Cancer

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Status: Terminated Condition: Prostate Cancer; Prostatic Neoplasms

Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Status: Recruiting Condition: Hormone Refractory Prostate Cancer

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Active, not recruiting Condition: Urothelial Carcinoma

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)
Status: Not yet recruiting Condition: Breast Cancer; Lung Cancer; Recurrent Brain Metastases; Progressive Brain Metastases

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes6,372,780<disabled>TREATMENT OF CANCER
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes6,387,946<disabled>TREATMENT OF CANCER
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes7,241,907<disabled>Y
Sanofi Aventis Us
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes5,847,170<disabled>YY
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology